chemistry proceedings

MDPI

Proceeding Paper

Cyclic 1H-Phospolane Oxides as a Potential Candidate for Cancer Therapy †

Tatyana V. Tyumkina [1,*], Denis N. Islamov [1], Alevtina L. Makhamatkhanova [1] and Marina I. Mallyabaeva [2]

[1] Institute of Petrochemistry and Catalysis, Ufa Federal Research Center, Russian Academy of Sciences, 141 Prospekt Oktyabrya, 450075 Ufa, Russia
[2] Federal State Budgetary Educational Institution of Higher Education, Ufa State Petroleum Technical University, 1 Kosmonavtov st., 450064 Ufa, Russia
* Correspondence: ttvnmr@gmail.com; Tel.: +7-917-34-604-91
† Presented at the 26th International Electronic Conference on Synthetic Organic Chemistry, 15–30 November 2022; Available online: https://sciforum.net/event/ecsoc-26.

Abstract: Organophosphorus compounds have been investigated for agricultural and medicinal applications for decades, and a considerable number of phosphorus-containing drugs have achieved commercial success. A recent review by P. Finkbeiner et al. has shown that phosphine oxides and related phosphorus-containing functional groups are valuable polar structural elements and that they deserve to be considered as a routine part of every medicinal chemist's toolbox. A new approach to the synthesis of previously hard-to-obtain 3-alkyl-1H-phospholanes oxides was developed by us. In order to assess the potential of five-membered cyclic organophosphorus compounds in cancer therapy, we carried out docking 3-buthyl-1H-phospholanes oxide and 2,3-dihydrophosphole in the binding site of 24 human proteins involved in oncogenesis processes. Proteins were selected using the PharmMapper in-house pharmacophore model database. The results are presented in the article.

Keywords: 1H-phospolane oxides; docking; cancer therapy

Citation: Tyumkina, T.V.; Islamov, D.N.; Makhamatkhanova, A.L.; Mallyabaeva, M.I. Cyclic 1H-Phospolane Oxides as a Potential Candidate for Cancer Therapy. *Chem. Proc.* **2022**, *12*, 49. https://doi.org/10.3390/ecsoc-26-13713

Academic Editor: Julio A. Seijas

Published: 18 November 2022

1. Introduction

It is well known that organophosphorus compounds are used in medicine, moreover, a significant number of phosphorus-containing drugs have achieved commercial success [1]. Recently, a review by P. Finkbeiner has shown [2] that most of the approved phosphorus-containing pharmaceuticals, for example drugs 1–6, contain a phosphate, a phosphoramide, or a phosphonate group, while phosphines, phosphinates, and phosphine oxides are rare (Scheme 1). For example, the phosphinate-based drug used to treat hypertension is fosinopril (**7**). Recently, ridaforolimus (**12**), a dimethylphosphinic ester containing inhibitor of mammalian target of rapamycin (mTOR), progressed into phase III clinical studies for the treatment of sarcoma, and the anaplastic lymphoma kinase (ALK) inhibitor brigatinib (**13**) became the first drug containing a phosphine oxide motif that was approved for the treatment of patients with metastatic non-small-cell lung cancer (NSCLC) [3,4].

At the same time, new approaches to the synthesis of previously undescribed cyclic phospholane oxides are being developed.



Scheme 1. Selected examples of phosphorus-containing drugs.

We have accumulated significant experience in the development of effective one-pot methods for the synthesis of five-membered phosphacarbocycles via transmetalation of aluminacarbocycles, obtained by catalytic cycloalumination [5–7] of olefins with $AlEt_3$ in the presence of Cp_2ZrCl_2 as a catalyst, by PCl_3 (Scheme 2).



R = *n*-C_4H_9 (**a**), *n*-C_6H_{13} (**b**), *n*-C_8H_{17} (**c**), -CH_2-Ph (**d**).

Scheme 2. Synthesis of the 3-alkyl(aryl)-1H-phospholane oxides via transmetalation of alumolanes by PCl_3.

The synthesized compounds are chemically stable and may be promising in cancer therapy. In order to predict the biological properties for oncotherapy of a number of phospholane oxides, we screened using the PharmMapper. Then docking was employed using AutoDock to find out the mechanism of binding of the macromolecular targets to

small active components under consideration, which made it possible to determine the role of the P=O(H) group in the interaction with targets.

2. Methods

A search for potential protein targets for the studied ligands was carried out using the PharmMapper in-house pharmacophore model database [8]. For this, the optimized ligand structures were saved as SDF files, which were then uploaded to a web server available at http://www.lilab-ecust.cn/pharmmapper/ (accessed on 22 October 2022). Pharmacophore mapping was carried out for the human protein targets set. From the resulting list of the potential human protein targets, only those involved in the processes of oncogenesis were selected for further study. AutoDock Tools (ADT) version 4.2.6 was used to carry out protein-ligand docking simulations [9]. The Discovery Studio Visualizer (version 21.1.0.20298, Dassault Systèmes, San Diego, CA, USA) [10] software was used to visualize the docking results.

3. Results and Discussion

The potential human protein targets were identified for model compound **15a**. Two diastereomers were taken into consideration with energy energetically lowest *twist* conformation (Scheme 3). The screening results showed 17 ranked targets listed in Table 1, confirming the possibility of interaction between the model compound and some indications. The highest fit scores for both isomers was characterized the androgen receptor, which is a member of the steroid/nuclear receptor superfamily and which functions as a transcription factor [11]. This receptor is activated by binding to androgenic hormones that regulate male sex development [12]. Reactivation of the androgen receptor occurs in recurrent prostate cancer [13], making this protein a potential target for prostate cancer therapy.



R_PS; δ S_P,S; δ S_P,R; λ R_P,R; λ

Scheme 3. Diastereomers of phospholane.

Table 1. Potential targets and indications of compound **2a** (RR configuration) by PharmMapper.

Target	PDBID	Normalized Fit Score
Androgen receptor	2ao6	0.7474
Progesterone receptor	1sqn	0.7377
Placenta growth factor-1	1fzv	0.5995
α-Catenin	1h6g	0.5987
α-Tocopherol transfer protein	1oiz	0.5734
Proto-oncogene tyrosine-protein kinase Src	1o4j	0.5167
Glyoxalase I	1qin	0.492
Prostatic acid phosphatase	1nd5	0.4819
Glycogen synthase kinase-3 β	1q4l	0.4192
Retinoic acid receptor beta	1xap	0.3296

Table 1. *Cont.*

Target	PDBID	Normalized Fit Score
Glucocorticoid receptor	1p93	0.3283
Growth factor receptor	1 × 0n	0.3272
Leukotriene A(4) hydrolase	1hs6	0.2997
Vitamin D nuclear receptor	1s0z	0.2799
Growth factor receptor-bound protein	2auh	0.256
Cysteine aspartyl protease-3	1nms	0.2223

The receptor was selected for the molecular docking simulation (Figure 1). Accordingly, the bioactive molecule in lowest conformation forms intermolecular interactions between the P=O group and the residues. The active sites of binding region in the receptor for the co-crystallized structure, which taken for comparison, were differ.



(**a**) (**b**)

Figure 1. 2-D diagram showing the intermolecular interactions with the active site residues of the androgen receptor of (**a**) co-crystallized ligand and (**b**) RR phospholane. Hydrophobic interactions are colored in light pink, unfavorable positive-positive interaction is colored in red, van der Waals interactions is colored in mint green, conventional hydrogen bonding is colored in green.

An free binding energy and final intermolecular energy, as well as an inhibition constant for each of the docked bioactive molecules, were estimated (Table 2). In terms of inhibitory activity, phospholane is clearly lower to the co-crystalized ligand (FBE = −10.04 kcal/mol, Ki = 43.69 nM).

Table 2. The lowest energy docked conformation of studied phospholanes.

Ligand	FBE, kcal/mol	FIE, kcal/mol	Ki
15a RR_S	−5.13	−6.02	174.02 µM
15a SS_N	−5.19	−6.09	155.83 µM
15b RR_S	−5.47	−6.96	97.98 µM
15b SS_N	−5.69	−7.18	67.23 µM
15c RR_S	−6.00	−8.09	39.75 µM
15c SS_N	−6.07	−8.16	35.53 µM
15d RS_S	−6.18	−6.77	29.71 µM
15d SR_N	−6.30	−6.89	24.19 µM
15a′ RR_S	−5.05	−6.24	199.21 µM
15a′ SS_N	−5.80	−6.99	55.93 mM

In the case of RR phospholane interaction with the active site of the androgen receptor, the hydrogen bonds were formed with the P=O functional group. Out of the total interactions, there was a lack of hydrophobic contacts, obviously; therefore, with an increase in chain length of the alkyl substituent, an increase in the binding energy was observed. It should be noted that the effect of stereochemistry on the energy parameters was also manifested. Moreover, we have docked the tautomeric form P-OH [14], which can exist at the equilibrium concentration (denoted as 15′) known for phosphine oxides (Table 2).

4. Conclusions

In summary, the potential anticancer activity for new 1H-phospolane oxides was identified. The androgen receptor was selected for the molecular docking simulation, as a result a binding site between the P=O and protein was shown. It was found that the design of the substituent in position 3 helped to model the binding activity.

Author Contributions: Conceptualization, T.V.T.; methodology, validation, and execution of chemistry experiments, D.N.I., M.I.M., and A.L.M.; manuscript preparation, M.I.M. and T.V.T. All authors have read and agreed to the published version of the manuscript.

Funding: The work was carried out within approved plans for research projects at the IPC RAS State Registration No. FMRS-2022-0074.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data available on request.

Acknowledgments: The structural studies of the synthesized compounds were performed on the equipment of «Agidel» Collective Usage Center of Ufa Federal Research Center at the Institute of Petrochemistry and Catalysis, Ufa Federal Research Center, Russian Academy of Sciences.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Finkbeiner, P.; Hehn, J.P.; Gnamm, C. Phosphine Oxides from a Medicinal Chemist's Perspective: Physicochemical and In Vitro Parameters Relevant for Drug Discovery. *J. Med. Chem.* **2020**, *63*, 7081–7107. [CrossRef] [PubMed]
2. Rodriguez, J.B.; Gallo-Rodriguez, C. The Role of the Phosphorous Atom in Drug Design. *Chem. Med. Chem.* **2019**, *14*, 190–216. [PubMed]
3. Markham, A. Brigatinib: First Global Approval. *Drugs* **2017**, *77*, 1131–1135. [CrossRef] [PubMed]
4. Huang, W.S.; Liu, S.; Zou, D.; Thomas, M.; Wang, Y.; Zhou, T.; Romero, J.; Kohlmann, A.; Li, F.; Qi, J.; et al. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. *J. Med. Chem.* **2016**, *59*, 4948–4964. [CrossRef] [PubMed]
5. Ibragimov, A.G.; Khafizova, L.O.; Khusainova, L.I.; Tyumkina, T.V.; Dzhemilev, U.M. Joint cycloalumination of ethylene and other unsaturated compounds with $EtAlCl_2$ in the presence of Cp_2ZrCl_2. Synthesis of aluminacarbocycles. *Russ. J. Org. Chem.* **2010**, *46*, 474–479. [CrossRef]
6. Dzhemilev, U.M.; Ibragimov, A.G. Catalytic cyclometalation reaction of unsaturated compounds in synthesis of magnesa- and aluminacarbocycles. *J. Organomet. Chem.* **2010**, *695*, 1085–1110. [CrossRef]
7. Khafizova, L.O.; Khusainova, L.I.; Tyumkina, T.V.; Dzhemilev, U.M. One-pot synthesis of borolanes by reaction of aluminacyclopentanes with $BF_3 \cdot Et_2O$. *Russ. J. Org. Chem.* **2012**, *48*, 755–760. [CrossRef]
8. Wang, X.; Shen, Y.; Wang, S.; Li, S.; Zhang, W.; Liu, X.; Lai, L.; Pei, J.; Li, H. PharmMapper 2017 update: A web server for potential drug target identification with a comprehensive target pharmacophore database. *Nucleic Acids Res.* **2017**, *45*, W356–W360. [CrossRef] [PubMed]
9. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *J. Comput. Chem.* **2009**, *30*, 2785–2791. [CrossRef] [PubMed]
10. BIOVIA Dassault Systèmes. *Discovery Studio Visualizer*; v21.1.0.20298; Dassault Systèmes: San Diego, CA, USA, 2020.
11. Gregory, C.W.; Hamil, K.G.; Kim, D.; Hall, S.H.; Pretlow, T.G.; Mohler, J.L.; French, F.S. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen regulated genes. *Cancer Res.* **1998**, *58*, 5718–5724. [PubMed]
12. Quigley, C.A.; de Bellis, A.; Marschke, K.B.; El-Awady, M.K.; Wilson, E.M.; French, F.S. Androgen Receptor Defects: Historical, Clinical, and Molecular Perspectives. *Endocr. Rev.* **1995**, *16*, 271–321. [CrossRef] [PubMed]

13. Gregory, C.W.; He, B.; Johnson, R.T.; Ford, O.H.; Mohler, J.L.; French, F.S.; Wilson, E.M. A mechanism for androgen receptor mediated prostate cancer recurrence after androgen deprivation therapy. *Cancer Res.* **2001**, *61*, 4315–4319. [PubMed]
14. Schlemminger, I.; Saida, Y.; Groger, H.; Maison, W.; Durot, N.; Sasai, H.; Shibasaki, M.; Martens, J. Concept of Improved Rigidity: How to Make Enantioselective Hydrophosphonylation of Cyclic Imines Catalyzed by Chiral Heterobimetallic Lanthanoid Complexes Almost Perfect. *J. Org. Chem.* **2000**, *65*, 4818–4825. [CrossRef] [PubMed]